NEUROSCIENCE TECHNOLOGIES collaborates with scientists from different Universities around the world:
- King’s College London, London, United Kingdom
- Università La Sapienza, Rome, Italy
- Universitat Autònoma de Barcelona, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- University of Cambridge, United Kingdom
- University College London, London, United Kingdom
- Yale University, New Haven, CT, USA
NEUROSCIENCE TECHNOLOGIES also participates in the European project Europain, a public-private consortium under the umbrella of Innovative Medicines Initiative (IMI), engaging 21 partners from all over Europe in order to elucidate chronic pain mechanisms and identify find new and better biomarkers that can improve the development of new treatments against chronic pain.
Europain has established an international team of leading researchers and clinicians, from both academia and industry, in order to undertake multidisciplinary translational research, which will: 1) increase the understanding of chronic pain mechanisms; 2) help to develop novel analgesics; 3) develop better biomarkers for pain; with the ultimate aim to: 4) improve the lives of people suffering from chronic pain.
The consortium network involves renowned scientists representing 12 renowned European Universities: King’s College London (Academic lead), University College London, Imperial College, the University of Oxford, the University of Kiel, the Medical Faculty Mannheim, Heidelberg University, the Technische Universität München, the Goethe University of Frankfurt, the BG University Hospital Bergmannsheil of Bochum, the University Hospitals of Aarhus, Rigshospitalet, Copenhagen, University of Southern Denmark, and Neuroscience Technologies. It also involves the research resources and expertise of Europe’s most active pharmaceutical companies working in the field of analgesics, including AstraZeneca (co-ordinator), Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Esteve, Pfizer, Sanofi-Aventis, UCB Pharma.